These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 2597493

  • 1. Intraperitoneal therapy with interferon-alpha in CAPD patients with relapsing bacterial peritonitis.
    Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Cantaluppi A, Salit M, Lamperi S.
    ASAIO Trans; 1989; 35(3):421-3. PubMed ID: 2597493
    [Abstract] [Full Text] [Related]

  • 2. Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy.
    Carozzi S, Nasini MG, Kunkl A, Cantarella S, Lamperi S.
    ASAIO Trans; 1988; 34(3):635-9. PubMed ID: 3264176
    [Abstract] [Full Text] [Related]

  • 3. Interferon-gamma (IFN-gamma) as in vitro enhancing factor of peritoneal macrophage defective bactericidal activity during continuous ambulatory peritoneal dialysis (CAPD).
    Lamperi S, Carozzi S.
    Am J Kidney Dis; 1988 Mar; 11(3):225-30. PubMed ID: 3125740
    [Abstract] [Full Text] [Related]

  • 4. Bacterial peritonitis and beta-2 microglobulin (B2M) production by peritoneal macrophages (PM0) in CAPD patients.
    Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Canepa M, Zanin T, Cantaluppi A, Salit M.
    Adv Perit Dial; 1990 Mar; 6():106-9. PubMed ID: 1982784
    [Abstract] [Full Text] [Related]

  • 5. Cytokine-induced peritoneal fibrosis in CAPD. Effects of Ca++ and 1,25(OH)2D3.
    Carozzi S, Nasini MG, Caviglia PM, Schelotto C, Santoni O, Barocci S, Versace F, Cantaluppi A, Salit M, Lamperi S.
    ASAIO Trans; 1989 Mar; 35(3):418-20. PubMed ID: 2512968
    [Abstract] [Full Text] [Related]

  • 6. Serial peritoneal macrophage function studies in CAPD patients with peritonitis.
    Lin CY, Huang TP.
    Adv Perit Dial; 1990 Mar; 6():114-9. PubMed ID: 1982786
    [Abstract] [Full Text] [Related]

  • 7. Peritonitis prevention in CAPD.
    Carozzi S, Lamperi S.
    Clin Nephrol; 1988 Mar; 30 Suppl 1():S45-8. PubMed ID: 3141093
    [Abstract] [Full Text] [Related]

  • 8. Intraperitoneal immunoglobulin (IG) treatment in prophylaxis of bacterial peritonitis in CAPD.
    Lamperi S, Carozzi S, Nasini MG.
    Biomater Artif Cells Artif Organs; 1987 Mar; 15(1):151-9. PubMed ID: 3329538
    [Abstract] [Full Text] [Related]

  • 9. Immunological defenses in CAPD.
    Lamperi S, Carozzi S.
    Blood Purif; 1989 Mar; 7(2-3):126-43. PubMed ID: 2663033
    [Abstract] [Full Text] [Related]

  • 10. Peritoneal macrophage beta-2 microglobulin production and bacterial peritonitis in CAPD patients.
    Carozzi S, Nasini G, Schelotto C, Caviglia PM, Canepa M, Zanin T, Cantaluppi A, Salit M.
    ASAIO Trans; 1990 Mar; 36(3):M369-71. PubMed ID: 2174686
    [Abstract] [Full Text] [Related]

  • 11. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis.
    Tong MK, Leung KT, Siu YP, Lee KF, Lee HK, Yung CY, Kwan TH, Au TC.
    J Nephrol; 2005 Mar; 18(2):204-8. PubMed ID: 15931649
    [Abstract] [Full Text] [Related]

  • 12. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.
    Carozzi S, Nasini MG, Ravera M, Sanna A, Tirotta A, Lamperi S.
    Adv Perit Dial; 1997 Mar; 13():7-12. PubMed ID: 9360642
    [Abstract] [Full Text] [Related]

  • 13. Modulation of peritoneal macrophage antimicrobial activity by peritoneal dialysis fluid, Ca++, and 1,25(OH)2D3 in CAPD patients.
    Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Barocci S, Cantaluppi A, Salit M.
    ASAIO Trans; 1990 Mar; 36(3):M467-9. PubMed ID: 2174688
    [Abstract] [Full Text] [Related]

  • 14. Peritoneal dialysis fluid (PDF) C++ and 1,25(OH)2D3 modulate peritoneal macrophage (PM0) antimicrobial activity in CAPD patients.
    Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Barocci S, Cantaluppi A, Salit M.
    Adv Perit Dial; 1990 Mar; 6():110-3. PubMed ID: 1982785
    [Abstract] [Full Text] [Related]

  • 15. Suppressor resident peritoneal macrophages and peritonitis incidence in continuous ambulatory peritoneal dialysis.
    Lamperi S, Carozzi S.
    Nephron; 1986 Mar; 44(3):219-25. PubMed ID: 2946966
    [Abstract] [Full Text] [Related]

  • 16. Peritoneal membrane defence mechanism in CAPD.
    Lamperi S, Carozzi S, Nasini MG.
    Contrib Nephrol; 1987 Mar; 57():69-78. PubMed ID: 3315441
    [No Abstract] [Full Text] [Related]

  • 17. Interleukin-1 and its naturally occurring antagonist in peritoneal dialysis patients.
    Moutabarrik A, Nakanishi I, Namiki M, Tsubakihara Y.
    Clin Nephrol; 1995 Apr; 43(4):243-8. PubMed ID: 7606878
    [Abstract] [Full Text] [Related]

  • 18. Relationship of IgG, C3 and transferrin with opsonising and bacteriostatic activity of peritoneal fluid from CAPD patients and the incidence of peritonitis.
    McGregor SJ, Brock JH, Briggs JD, Junor BJ.
    Nephrol Dial Transplant; 1987 Apr; 2(6):551-6. PubMed ID: 3126457
    [Abstract] [Full Text] [Related]

  • 19. Ca++ and 1,25(OH)2D3 enhance peritoneal macrophage (PMPhi) antimicrobial functions in CAPD.
    Carozzi S, Nasini MG, Schelotto C, Caviglia P, Santoni O, Barocci S, Versace F, Cantaluppi A, Salit M, Lamperi S.
    Adv Perit Dial; 1989 Apr; 5():103-10. PubMed ID: 2577389
    [Abstract] [Full Text] [Related]

  • 20. Role of catheter removal in therapy of bacterial peritonitis of continuous ambulatory peritoneal dialysis.
    Zappacosta AR, Perras ST.
    ASAIO Trans; 1989 Apr; 35(1):40-5. PubMed ID: 2659051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.